Loading
A phase 2/3 trial of Alectinib in non-small-cell lung cancer, run by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, active and no longer recruiting.
Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms is a phase 2/3 interventional study registered as NCT05987956 by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, with 600 participants enrolled, started 2026-03-18 and due to reach its primary completion in 2026-11-18. Interventions recorded: ALECENSA - alectinib hydrochloride capsule.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Alectinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/